Related Experiment Videos
Issues and challenges for antiangiogenic therapies
1School of Medicine, Indiana University, Indianapolis, USA. kathmill@iupui.edu
Breast Cancer Research and Treatment
|October 2, 2002
Summary
Angiogenesis, the growth of new blood vessels, is crucial for tissue development and repair. Inhibiting tumor angiogenesis offers a targeted therapy approach with potential to spare normal tissues.
Area of Science:
- Biomedical Science
- Molecular Biology
- Oncology
Background:
- Angiogenesis is the formation of new blood vessels from existing ones, essential for tissue growth, repair, and reproduction.
- Tumors require angiogenesis to obtain nutrients and oxygen, often outgrowing their host tissue's vascular supply and becoming hypoxic.
- Hypoxia in tumors triggers the release of angiogenic factors, which stimulate new blood vessel growth.
Purpose of the Study:
- To explore the potential of inhibiting angiogenesis as a targeted cancer therapy.
- To understand the molecular mechanisms tumors use to induce angiogenesis.
- To identify novel therapeutic targets for anti-angiogenic drug development.
Main Methods:
- Elucidation of molecular mechanisms underlying tumor-induced angiogenesis.
- Identification of specific protein mediators, ligands, receptors, and signal-transduction pathways involved in angiogenesis.
- Evaluation of drug candidates targeting angiogenic mechanisms in preclinical and clinical settings.
Main Results:
- Tumor-induced angiogenesis is a complex process driven by hypoxia and mediated by specific protein factors.
- Several molecular targets and signaling pathways involved in angiogenesis have been identified.
- Drug candidates targeting angiogenesis are under investigation for cancer treatment, including breast cancer.
Conclusions:
- Inhibiting angiogenesis is a promising strategy for cancer therapy due to its relative specificity to rapidly growing tumor tissues.
- Understanding the molecular basis of angiogenesis provides targets for novel therapeutic agents.
- Clinical evaluation of anti-angiogenic drugs necessitates advanced methodologies and technologies to assess complex pharmacology and improve patient outcomes.